Communities demand ViiV/GSK accelerate access to CAB-LA in LMICs

Back to the "HIV and Co-Infections News" list

A statement was released from nearly 200 community representatives and organisations, concerned about the continued delay by ViiV/GSK to announce a cabotegravir long-acting injectable (CAB-LA) access plan in low- and middle-income countries (LMICs).

CAB-LA offers a badly needed option for individuals at risk of HIV infection for whom daily PrEP use is not preferred or feasible. It helps overcome many barriers associated with daily pills while adding to the much-needed diversity in HIV prevention tools that the community has for years been calling for.

The statement is calling upon ViiV/GSK to immediately license CAB-LA to generic manufacturers to ensure its affordable and widespread access in LMICs. The community is asking them to urgently update their access plans using the dolutegravir license agreement and geographic scope as the absolute minimum, while also ensuring the licensing process with generic manufacturers is open and transparent.

ViiV/GSK has set a very high standard in ensuring equity for all people to access its antiretrovirals. This is the time to act and ramp up on that standard. The young men, women, and the entire community aspiring for an HIV free generation eagerly await their announcement that responds to the asks contained in the statement. The statement urges ViiV/GSK to live up to their reputation as an innovator with public health at the heart of all their access policies.

View full statement here.

 

Source : AfroCAB

Get involved

Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?

Subscribe

Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.